EKTERLY Trademark

Trademark Overview


On Friday, March 10, 2023, a trademark application was filed for EKTERLY with the United States Patent and Trademark Office. The USPTO has given the EKTERLY trademark a serial number of 97832368. The federal status of this trademark filing is PUBLISHED FOR OPPOSITION as of Tuesday, January 30, 2024. This trademark is owned by Kalvista Pharmaceuticals Limited. The EKTERLY trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of angioedema; pharmaceutical preparations for the treatment of hereditary angioedema; pharmaceutical preparations for the treatment of bradykinin mediated inflammatory disorders; pharmaceutical preparations for the treatment of diseases and disorders mediated by the contact activation system; pharmaceutical preparations for the treatment of plasma kallikrein or factor XIIa mediated diseases or disorders; pharmaceutical preparations containing sebetralstat for the treatment of angioedema, hereditary angioedema, bradykinin mediated inflammatory disorders, plasma kallikrein or factor XIIa mediated diseases or disorders, or diseases and disorders mediated by the contact activation system
ekterly

General Information


Serial Number97832368
Word MarkEKTERLY
Filing DateFriday, March 10, 2023
Status686 - PUBLISHED FOR OPPOSITION
Status DateTuesday, January 30, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 30, 2024

Trademark Statements


Goods and ServicesPharmaceutical preparations for the treatment of angioedema; pharmaceutical preparations for the treatment of hereditary angioedema; pharmaceutical preparations for the treatment of bradykinin mediated inflammatory disorders; pharmaceutical preparations for the treatment of diseases and disorders mediated by the contact activation system; pharmaceutical preparations for the treatment of plasma kallikrein or factor XIIa mediated diseases or disorders; pharmaceutical preparations containing sebetralstat for the treatment of angioedema, hereditary angioedema, bradykinin mediated inflammatory disorders, plasma kallikrein or factor XIIa mediated diseases or disorders, or diseases and disorders mediated by the contact activation system

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, March 30, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameKalvista Pharmaceuticals Limited
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressWiltshire SP40BF
GB

Party NameKalvista Pharmaceuticals Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressWiltshire SP40BF
GB

Trademark Events


Event DateEvent Description
Tuesday, January 30, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 30, 2024PUBLISHED FOR OPPOSITION
Wednesday, January 10, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, December 27, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, December 26, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, December 26, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, December 26, 2023ASSIGNED TO LIE
Monday, July 31, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, May 12, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, May 12, 2023NON-FINAL ACTION E-MAILED
Friday, May 12, 2023NON-FINAL ACTION WRITTEN
Friday, May 5, 2023ASSIGNED TO EXAMINER
Thursday, March 30, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, March 14, 2023NEW APPLICATION ENTERED